Biotech

Paradromics, Inc., based in Austin, Texas, is at the forefront of brain-computer interface (BCI) technology, focusing on high-data rate and high-reliability applications aimed at transforming brain health. Founded by CEO Matt Angle, the company blends expertise in neurotechnology, data science, and medical devices to create advanced BCI platforms that promise groundbreaking applications. The team includes notable figures such as COO James Burrows and CSO Vikash Gilja, contributing their extensive experience to drive the development of innovative neurotech solutions. In 2023, Paradromics received FDA Breakthrough Device Designation for its speech decoding technology, marking a significant milestone in its commitment to advancing healthcare through neurotechnology. Generated from the website

Aileron Therapeutics, Inc, based in Watertown, MA, is a biopharmaceutical company focused on developing innovative therapies for orphan pulmonary and fibrosis conditions. With the recent acquisition of Lung Therapeutics and a concurrent $18M private investment, Aileron is well-positioned to advance its pipeline of first-in-class medicines to address significant unmet medical needs in these diseases. The company's lead clinical programs include LTI-03, a pioneering compound for idiopathic pulmonary fibrosis (IPF), and LTI-01, a first-in-class treatment for loculated pleural effusion (LPE). Aileron's management team, led by CEO Manuel C. Aivado, M.D., Ph.D, brings extensive experience in clinical development and pharmacovigilance, ensuring the company's commitment to delivering better treatment options for patients with life-threatening pulmonary conditions.Generated from the website

Next-ChemX has developed a novel membrane-based ion extraction technology that mimics biophysical processes in nature. Their founding team is experienced in developing advanced materials and setting up commercial production with marketing worldwide.